The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

A Missouri lawmaker is putting the high price of medication under the microscope. “My biggest issue is these PBMs, and what they’re supposed to do is they’re supposed to get discounts from big pharma on drugs and pass those along to people at local pharmacies,